Cilgavimab Antibody is a research-grade biosimilar monoclonal antibody targeting Spike glycoprotein. It is a human IgG1, kappa antibody. Reactivity: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Spike glycoprotein (RBD) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.
Product Name:
Cilgavimab Antibody
SKU:
GXBS00488
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
Spike glycoprotein
Isotype:
IgG1, kappa
Host Species:
Human
Reactivity:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
Spike glycoprotein, Spike, S glycoprotein, RBD
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
